TL;DR
Insight is provided into metabolic heterogeneity in HF and OGDHL is identified as a potential regulator of cardiac metabolic remodeling, which was consistently downregulated in experimental HF models.
A progressive rat model of CKM syndrome is established by combining high-fat/high-sucrose exposure with adenine-induced renal stress, capturing temporal changes from early metabolic dysregulation to advanced multi-organ injury and highlights renal lipotoxic remodeling as a potential therapeutic target in CKM progressio...
To elucidate the molecular characteristics of synergistic interactions across the clinical stages of coronary heart disease (CHD)—specifically stable angina pectoris (SAP), unstable angina pectoris (UAP), and acute myocardial infarction (AMI)—through integrated metabolomic and proteomic analyses. Based on a cohort incl...
The primordial role of metabolic pathways and adipokines as therapeutic targets for HF management is highlighted, and six cardiomyopathy genes were novel for HF and associated with cardiac structure and function.
Whether data-driven clustering based on metabolomic biomarkers could define distinct prediabetes subtypes with differential type 2 diabetes, cardiovascular disease, and chronic kidney disease risk is examined and metabolomics-based subtypes may improve risk stratification and support precision prevention strategies.
Sex-stratified molecular-clinical networks define prognostically distinct HFpEF subgroups with robust external validation, supporting precision medicine strategies targeting high-risk cluster patients in sex-specific manner.
It is suggested that extra-cardiac metabolic pathways, particularly liver-centered mechanisms, may contribute to the therapeutic benefits of SGLT2 inhibitors in HFpEF and provide new insights into inter-organ metabolic regulation.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
